skip to main content

Kidney / Renal Cancer

Study provides important findings for kidney cancer with gene mutation

The findings show that the patients who had renal tumors with TFEB amplification were significantly older than patients with renal tumors housing TFE3 or TFEB translocation. Further, renal tumors with TFEB amplification, known to be associated with poor prognosis, were seen to be at least three times as common as those with TFEB translocation.

Why don't all types of renal cell carcinoma respond to immunotherapy?

By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers have identified the cells from which different subtypes originate, the pathways involved and how the tumor microenvironment impacts cancer development and response to treatment.

Biomarker Could Help Identify MiTF Renal Cell Carcinoma

High expression levels of the gene TRIM63 can serve as an accurate and sensitive biomarker of a subtype of kidney cancer known as microphthalmia-associated transcription factor family aberration-associated renal cell carcinomas — or MiTF renal cell carcinoma.

Researchers may have Found a Way to Diagnose Rare Kidney Cancer Earlier

Using next-generation RNA sequencing techniques, a team of scientists from the University of Michigan Rogel Cancer Center has uncovered the gene signature of chromophobe renal cell carcinoma (ChRCC) and have extensively tested the expression of three new biomarkers.

Immunotherapy cancer drugs may impact vision

Although it is rare, knowledge of this risk is important both for the ophthalmologists who treat it and for the oncologists prescribing the anti-cancer treatment, say Michigan Medicine researchers. The cases of three recent patients, published in JAMA Ophthalmology, highlight the issue. Patients receiving immune checkpoint inhibitors developed uveal effusions and eye inflammation that affected their vision.

Pages